---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-26-000008"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:49:47.621767+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026

## Summary
- Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.
- Cash, equivalents, investments $128.7M at Dec 31, 2025, funding operations into 2H 2028.
- Silevertinib Phase 2 NSCLC update with preliminary DOR/PFS expected Q2 2026; randomized GBM trial to start Q2 2026.
- R&D expenses $33.6M in FY2025, down 34% YoY due to restructuring and focus on silevertinib.

## SEC filing metadata
- accession: 0001701541-26-000008
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000008/0001701541-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000008/bdtx-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-26-000008
- JSON: https://secwatch.observer/filing/0001701541-26-000008.json
- Plain text: https://secwatch.observer/filing/0001701541-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.